Country Reports

Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations. These fundamentals include a revamped market access process, a high-quality yet affordable manufacturing base, and a budding reputation as one of the…

Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics covered in this report range from the successes of Turkey’s Healthcare Transformation Programme…

Topics covered in this report – which features the exclusive insights of government ministers, the heads of local pharma champions as well as multinational affiliate leaders – include the potential impact of Algeria’s sweeping new healthcare law, the establishment of the country’s first National Cancer Plan, global companies’ scramble to localise manufacturing operations, an investment…

Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Matahir Mohamad spearheading a bold health policy reform. Also explored is the emergence of the halal medicine niche – where Malaysia…

Despite its small population size, Hong Kong has long held a strategic interest for the healthcare and life sciences industries, whether as a testbed for innovative products and service delivery models as a result of its efficient regulatory approval system or as an incubator for start-up companies looking to penetrate both mainland Chinese and international…

Through interviews with the heads of some of India’s leading domestic pharmaceutical companies, this report delves into the biologics, biosimilars and new chemical entities being developed in India and taken abroad; the nation’s hubs of development and innovation, notably the northern state of Gujarat; and how Indian companies have stepped up their quality compliance game…

A light regulatory touch has long attracted companies to establish R&D and manufacturing plants for generic pharmaceuticals in Malta in the knowledge that products developed on the island can be launched globally immediately on the expiry of the originator drug – a massive draw factor for cost- and time-concious generics companies.   Building on this…